PT - JOURNAL ARTICLE AU - Mwimanzi, Francis AU - Lapointe, Hope AU - Cheung, Peter K. AU - Sang, Yurou AU - Yaseen, Fatima AU - Umviligihozo, Gisele AU - Kalikawe, Rebecca AU - Datwani, Sneha AU - Omondi, F. Harrison AU - Burns, Laura AU - Young, Landon AU - Leung, Victor AU - Ennis, Siobhan AU - Agafitei, Olga AU - Basra, Simran AU - Lim, Li Yi AU - Ng, Kurtis AU - Pantophlet, Ralph AU - Brumme, Chanson J. AU - Montaner, Julio S.G. AU - DeMarco, Mari L. AU - Holmes, Daniel T. AU - Simons, Janet AU - Niikura, Masahiro AU - Romney, Marc G. AU - Brumme, Zabrina L. AU - Brockman, Mark A. TI - Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose AID - 10.1101/2022.01.06.22268745 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.06.22268745 4099 - http://medrxiv.org/content/early/2022/01/06/2022.01.06.22268745.short 4100 - http://medrxiv.org/content/early/2022/01/06/2022.01.06.22268745.full AB - Background Two-dose mRNA vaccines reduce COVID-19 related hospitalization and mortality, but immune protection declines over time. As such, third vaccine doses are now recommended, particularly for older adults. We examined immune response durability up to six months after two vaccine doses, and immunogenicity after a third vaccine dose, in 151 adults ranging in age from 24 to 98 years.Methods Specimens were collected from 81 healthcare workers (median age 41 years), 56 older adults (median 78 years) and 14 COVID-19 convalescent individuals (median 48 years), at one, three and six months following the second vaccine dose, and from 15 HCW, 28 older adults and 3 convalescent individuals at one month following a third vaccine dose. Binding antibodies to the SARS-CoV-2 spike receptor binding domain were quantified using a commercial immunoassay. Virus neutralizing activity was assessed using a live SARS-CoV-2 infection assay.Results Compared to healthcare workers, older adults displayed ∼0.3 log10 lower peak binding antibodies one month after the second vaccine dose (p<0.0001) and modestly faster rates of antibody decline thereafter (p=0.0067). A higher burden of chronic health conditions was independently associated with faster rates of antibody decline after correction for age, sociodemographic factors, and vaccine-related variables. Peak neutralizing activity was 4-fold lower in older adults one month after the second vaccine dose (p<0.0001) and became undetectable in the majority of individuals by six months. One month after a third vaccine dose, binding antibodies and neutralizing activities surpassed peak values achieved after two doses in both healthcare workers and older adults, and differences between these groups were no longer statistically significant. Compared to both naïve groups, convalescent individuals displayed slower rates of binding antibody decline (p<0.006) and maintained higher neutralizing activity six months after the second vaccine dose.Conclusions Immune responses to two-dose COVID-19 mRNA vaccines are overall weaker in older adults, and also decline more quickly over time, compared to younger adults. A third COVID-19 mRNA vaccine dose enhanced binding and neutralizing antibodies to levels higher than those observed after two vaccine doses, but the rate of decline of these responses should be monitored, particularly in older adults with a higher burden of chronic health conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Public Health Agency of Canada through a COVID 19 Immunology Task Force COVID 19 Hot Spots Award (2020 HQ 000120 to MGR, ZLB, MAB), the Canadian Institutes for Health Research (GA2 177713 to MAB), the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID 19 awards (to MAB, MD, MN, RP, ZLB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). GU and FHO are supported by Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. LYL was supported by an SFU Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is an interim report from an ongoing study. Data from this report are available upon reasonable request to the authors in accordance with REB and institutional data sharing requirements. At the end of the study, all data will be deposited in a national database maintained by the COVID-19 Immunity Task Force.